Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Hepatocellular Carcinoma | Primary research

GSTM1 and GSTT1 null genotype increase the risk of hepatocellular carcinoma: evidence based on 46 studies

Authors: Shanli Li, Feng Xue, Yi Zheng, Pengtao Yang, Shuai Lin, Yujiao Deng, Peng Xu, Linghui Zhou, Qian Hao, Zhen Zhai, Ying Wu, Zhijun Dai, Shu Chen

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

It is well known that hepatocellular carcinoma (HCC) has been one of the most life-threatening diseases all over the world. Plenty of internal and extrinsic factors have been proven to be related to HCC, such as gene mutation, viral hepatitis, and Nitrosamines. Though previous studies demonstrated that glutathione S-transferase (GST) genotypes are associated with HCC, the conclusions are inconsistent. Therefore, we carried on a renewed meta-analysis to expound the connection between the null GSTM1, GSTT1 polymorphisms and the risk of HCC.

Methods

We searched PubMed, Web of Science, Embase, and CNKI databases to select qualified researches which satisfied the inclusion criteria up to July 31, 2018. Finally, we selected 41 articles with 6124 cases and 9781 controls in this meta-analysis. We use ORs and 95% confidence interval (CI) to evaluate the correlation intension between the GSTM1 and GSTT1 null genes and the risk of HCC. All the statistical processes were executed by Stata (version 12.0).

Results

The pooled analysis showed that both GSTM1 null genotypes (OR = 1.37, 95% CI = 1.18–1.59) and GSTT1 null genotypes (OR = 1.43, 95% CI = 1.23–1.66) increased the risk of HCC. And GSTM1–GSTT1 dual-null genotypes also increased the risk of HCC (OR = 1.58, 95% CI = 1.22–2.05). In the subgroup analysis, we obtained significant results among Asians when stratified by race, and the results are GSTM1 null OR = 1.44, 95% CI = (1.22–1.71), GSTT1 null OR = 1.48, 95% CI = (1.25–1.77), GSTM1–GSTT1 null OR = 1.58, 95% CI = (1.19–2.09), while we didn’t obtain significant results among Caucasians or Africans. Stratified analyses on the type of control indicated a higher risk of HCC associated with GSTM1, GSTT1 single null genotypes and GSTM1–GSTT1 dual-null genotypes in healthy people. No evidence of significant connection was discovered in chronic liver disease (CLD) except in GSTT1 single null.

Conclusions

Our study indicated that an individual who carries the GSTM1, GSTT1 single null genotypes and GSTT1–GSTM1 dual-null genotypes is more likely to develop HCC.
Appendix
Available only for authorised users
Literature
1.
2.
Wei K, Peng X, Liang Z, Cen H. Liver cancer epidemiology world. China Cancer. 2015;24(08):621–30.
3.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer J Clin. 2015;65(2):87–108.
4.
Abdel-Rahman O, Helbling D, Schob O, Eltobgy M, Mohamed H, Schmidt J, Giryes A, Mehrabi A, Iype S, John H, et al. Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: an updated systematic review of 81 epidemiological studies. J Evid-Based Med. 2017;10(4):245–54.PubMedCrossRef
5.
Yan G, Wang X, Sun C, Zheng X, Wei H, Tian Z, Sun R. Chronic alcohol consumption promotes diethylnitrosamine-induced hepatocarcinogenesis via immune disturbances. Sci Rep. 2017;7(1):2567.PubMedPubMedCentralCrossRef
6.
7.
Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, Franceschi S, Montella M, Polesel J, Zucchetto A, et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology. 2012;55(5):1416–25.PubMedCrossRef
8.
Cheng J, Zhong Y, Chen S, Sun Y, Huang L, Kang Y, Chen B, Chen G, Wang F, Tian Y, et al. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways. FASEB J. 2017;31(12):5530–42.PubMedPubMedCentralCrossRef
9.
Li R, Boerwinkle E, Olshan AF, Chambless LE, Pankow JS, Tyroler HA, Bray M, Pittman GS, Bell DA, Heiss G. Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis. 2000;149(2):451–62.PubMedCrossRef
10.
Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61(3):154–66.PubMedCrossRef
11.
12.
Dai Z, Feng C, Zhang W, Liu J, Cao X, Zhang H, Liu Y, Wang M, Liu X, Dai Z. Lack of association between cytotoxic T-lymphocyte antigen-4 gene polymorphisms and lymphoid malignancy risk: evidence from a meta-analysis. Ann Hematol. 2016;95(10):1685–94.PubMedCrossRef
13.
Zhou L, Zheng Y, Tian T, Liu K, Wang M, Lin S, Deng Y, Dai C, Xu P, Hao Q, et al. Associations of interleukin-6 gene polymorphisms with cancer risk: evidence based on 49,408 cancer cases and 61,790 controls. Gene. 2018;670:136–47.PubMedCrossRef
14.
15.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMed
16.
Imaizumi T, Higaki Y, Hara M, Sakamoto T, Horita M, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, et al. Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis. 2009;30(10):1729–34.PubMedCrossRef
17.
Kiran M, Chawla YK, Kaur J. Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. DNA Cell Biol. 2008;27(12):687–94.PubMedCrossRef
18.
Zhang Y, Deng C, Zhu Y. Study on genetic polymorphisms of xenobiotic metabolizing enzymes in hepatitis B virus-associated hepatic diseases. J Wenzhou Med Coll. 2005;35(06):464–7.
19.
Deng Z, Wei Y, Ma Y. Genetic deletion of GSTM1 and GSTT1 detoxicated enzymes in relation to hepatocellular carcinoma in Guangxi. Guangxi Sciences. 2005;12(01):55–7.
20.
Zhu M, Chen X, Zhou L. Association of genetic polymorphisms in glutathione S-transferases M1 with hepatitis B-related hepatocellular carcinoma. J Zhejiang Univ. 2005;34(02):35–9.
21.
Boccia S, Miele L, Panic N. The effect of CYP GST, and SULT polymorphisms and their interaction with smoking on the risk of hepatocellular carcinoma. Biomed Res Int. 2015;2015:179867.PubMedPubMedCentral
22.
Chen Y, Ding F, Xie Y-A. Study on gene polymorphisms of glutathione S-transferase GSTM1 and GSTT1 in high-risk families for liver cancer in Fusui county, Guangxi. Chin J of Oncol Prev and Treat. 2012;4(02):140–4.
23.
Tang Y, Li X, Liu T. A study of genetic polymorphisms of glutathione S-transferase in patients with hepatocellular carcinoma. Chin J Lab Diagn. 2012, 16(04):660–2.
24.
Li CG, Zhao ZM, Hu MG, Liu R. Predictive role of glutathione-S-transferase gene polymorphisms in risk and prognosis of hepatocellular carcinoma. Asian Pac J Cancer Prev APJCP. 2012;13(7):3247–52.PubMedCrossRef
25.
Sarma MP, Asim M, Medhi S, Bharathi T, Kar P. Hepatitis C virus related hepatocellular carcinoma: a case control study from India. J Med Virol. 2012;84(7):1009–17.PubMedCrossRef
26.
Xiao K, Li L, Peng M, Qin X, Peng T, Guo Y. Gene polymorphisms of GSTM1 and GSTT1 in the clustering families of hepatocellular carcinoma. Chin J Oncol Prev Treat. 2011;3(04):287–90.
27.
Wei Y, Long X, Liu Z, Ma Y, Deng Z. Genetic polymorphism of glutathione-S-transferase M1 and T1 in hepatocellular carcinoma and nasopharyngeal carcinoma. Cancer Prev Res. 2010;37(10):1162–5.
28.
Kao CC, Chen MK, Kuo WH, Chen TY, Su SC, Hsieh YH, Liu CL, Chou MC, Tsai HT, Yang SF. Influence of glutathione-S-transferase theta (GSTT1) and micro (GSTM1) gene polymorphisms on the susceptibility of hepatocellular carcinoma in Taiwan. J Surg Oncol. 2010;102(4):301–7.PubMedCrossRef
29.
Asim M, Khan LA, Husain SA, Husain S, Sarma MP, Ahmad I, Sharma JK, Sharma A, Sharma S, Thayumanavan L, et al. Genetic polymorphism of glutathione S transferases M1 and T1 in Indian patients with hepatocellular carcinoma. Dis Markers. 2010;28(6):369–76.PubMedPubMedCentralCrossRef
30.
Yang Z, Xie Y-A, Kuang Z, Luo X, Zhang W, Leng C. Relationship between genetic polymorphisms of glutathione-S-transferase M1, T1 genes and susceptibility to hepatocellular carcinoma in population of Fusui District of Guangxi Zhuang Autonomous Region. Chin J Caner Prev Treat. 2009;16(13):970–3.
31.
He S, Gu Y, Liao Z. Relationship between GSTM1 gene polymorphism, tobacco and alcohol habits and susceptibility to primary liver cancer. J Guangxi Medi Univ. 2008;25(04):567–8.
32.
Abd El-Moneim E, Younis FA, Allam N, Gameel K, Osman M. Gene deletion of glutathione S-transferase M1 and T1 and risk factors of hepatocellular carcinoma in Egyptian patients. Egypt J Immunol. 2008;15(2):125–34.PubMed
33.
Borentain P, Gerolami V, Ananian P, Garcia S, Noundou A, Botta-Fridlund D, Le Treut YP, Berge-Lefranc JL, Gerolami R. DNA-repair and carcinogen-metabolising enzymes genetic polymorphisms as an independent risk factor for hepatocellular carcinoma in Caucasian liver-transplanted patients. Eur J Cancer. 2007;43(17):2479–86.PubMedCrossRef
34.
Deng W. The study of correlation between the polymorphism of GST genes and familial susceptibility to hepatocellular carcinoma in the high incidence area of Guangxi. Master: Guangxi Medical University; 2006.
35.
Long XD, Ma Y, Wei YP, Deng ZL. The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res. 2006;36(1):48–55.PubMedCrossRef
36.
Ladero JM, Martinez C, Garcia-Martin E, Ropero P, Briceno O, Villegas A, Diaz-Rubio M, Agundez JA. Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: a study in the Spanish population. Eur J Cancer. 2006;42(1):73–7.PubMedCrossRef
37.
Guo H, Bian J, Jiang F, Wang Q, Zhang Z, Fan W, Wang Q, Zhu X, Tang B. The null genotypes ofGSTM1 and GSTT1 and the genetic susceptibility of prmiary liver cancer in Luoyang, China. Tumor. 2005;25(01):58–61.
38.
Long X, Ma Y, Wei Y, Deng Z. A study about the association of detoxication gene GSTM1 polymorphism and the susceptibility to aflatoxin B1-related hepatocellular carcinoma. Chin J Hepatol. 2005;13(09):668–70.
39.
He S, Qin J, Gu Y, Zhong W, Su S. Polymorphism analysis of GSTM1 and GSTT1 genes in patients with hepatocellular carcinoma. J Guangxi Med Univ. 2005;22(06):875–7.
40.
Gelatti U, Covolo L, Talamini R, Tagger A, Barbone F, Martelli C, Cremaschini F, Franceschi S, Ribero ML, Garte S, et al. N-Acetyltransferase-2, glutathione S-transferase M1 and T1 genetic polymorphisms, cigarette smoking and hepatocellular carcinoma: a case-control study. Int J Cancer. 2005;115(2):301–6.PubMedCrossRef
41.
Kirk GD, Turner PC, Gong Y, Lesi OA, Mendy M, Goedert JJ, Hall AJ, Whittle H, Hainaut P, Montesano R, et al. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomarkers Prev. 2005;14(2):373–9.PubMedCrossRef
42.
Ma D, Chen Y, Li Y, Zhao H, Xie X, Lu X. Glutathione-S-transferase M1 and T1 polymorphisms and susceptibility to liver cancer in hepatitis B surface antigen positive population. Med J Chin People’ s Armed Police Forces. 2005;16(09):660–2.
43.
Li S, Wu J, Ding J, Gao C, Cao H, Zhou X. Impact of Genetic polymorphisms of glutathione S-transferase T1, M1 on the risk of primary hepatocellular carcinoma in alcohol drinkers. Pract J Cancer. 2004;19(03):229–32.
44.
Yu MW, Yang SY, Pan IJ, Lin CL, Liu CJ, Liaw YF, Lin SM, Chen PJ, Lee SD, Chen CJ. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2003;95(19):1485–8.PubMedCrossRef
45.
Liu Z. Genetic polymorphism of GSTT1 and EPHX and the risk of Hepatocellular carcinoma from Guangxi district. Master: Guangxi Med Univ; 2003.
46.
Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S, Katoh T. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2003;129(6):355–60.PubMedCrossRef
47.
Chen SY, Wang LY, Lunn RM, Tsai WY, Lee PH, Lee CS, Ahsan H, Zhang YJ, Chen CJ, Santella RM. Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls. Int J Cancer. 2002;99(1):14–21.PubMedCrossRef
48.
Tiemersma EW, Omer RE, Bunschoten A, van’t Veer P, Kok FJ, Idris MO, Kadaru AM, Fedail SS, Kampman E. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2001;10(7):785–91.PubMed
49.
Sun CA, Wang LY, Chen CJ, Lu SN, You SL, Wang LW, Wang Q, Wu DM, Santella RM. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case–control study in Taiwan. Carcinogenesis. 2001;22(8):1289–94.PubMedCrossRef
50.
Zhu W, Chen Q, Luo C, Chu X, Wu M. Relationship study between gene polymorphism of CYP1A1, GSTM1 and genetic susceptibility of primary hepatocellar carcinoma. China J Cancer Prev Treat. 2001;8(06):572–4.
51.
Bian JC, Shen FM, Shen L, Wang TR, Wang XH, Chen GC, Wang JB. Susceptibility to hepatocellular carcinoma associated with null genotypes of GSTM1 and GSTT1. World J Gastroenterol. 2000;6(2):228–30.PubMedPubMedCentral
52.
Wu H, Chen M, Liu P, Zhang R. Relationship between GSTM1 gene polymorphism and genet ic susceptibility to primary hepatocellular carcinoma. Pract J Cancer. 2000;15(05):463–5.
53.
Yu MW, Chiu YH, Chiang YC, Chen CH, Lee TH, Santella RM, Chern HD, Liaw YF, Chen CJ. Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects. Am J Epidemiol. 1999;149(7):621–9.PubMedCrossRef
54.
Dong C, Zi X, Yu S, Han J. Relationship between deletion of slutathion S-trausferase gene and susceptibility to primary hepatocellular carcinoma. Chin J Public Health. 1997;16(03):15–6.
55.
Dong C, Yu S, Chen G, Deming Z, Fu Y. Polymorphisms of GSTT1 and M1 genotypes and their effects on elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Cancer Prev Res. 1997;24(06):327–9.
56.
Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology. 1995;109(4):1266–73.PubMedCrossRef
57.
Wang ZY, Zhou J, Luo L, Huang YL, Dong PD. Predictive role of glutathione-S-transferase gene polymorphisms in the survival of gastric cancer cases. Asian Pac J Cancer Prev: APJCP. 2012;13(4):1515–8.PubMedCrossRef
58.
Coric VM, Simic TP, Pekmezovic TD, Basta-Jovanovic GM, Savic-Radojevic AR, Radojevic-Skodric SM, Matic MG, Suvakov SR, Dragicevic DP, Radic TM, et al. GSTM1 genotype is an independent prognostic factor in clear cell renal cell carcinoma. Urol Oncol. 2017;35(6):409–17.PubMedCrossRef
59.
Sharma N, Singh A, Singh N, Behera D, Sharma S. Genetic polymorphisms in GSTM1, GSTT1 and GSTP1 genes and risk of lung cancer in a North Indian population. Cancer Epidemiol. 2015;39(6):947–55.PubMedCrossRef
60.
White DL, Li D, Nurgalieva Z, El-Serag HB. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol. 2008;167(4):377–89.PubMedCrossRef
61.
Song K, Yi J, Shen X, Cai Y. Genetic polymorphisms of glutathione S-transferase genes GSTM1, GSTT1 and risk of hepatocellular carcinoma. PLoS ONE. 2012;7(11):e48924.PubMedPubMedCentralCrossRef
62.
Shen YH, Chen S, Peng YF, Shi YH, Huang XW, Yang GH, Ding ZB, Yi Y, Zhou J, Qiu SJ, et al. Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk. Tumour Biol. 2014;35(5):4007–15.PubMedCrossRef
63.
Yuan BH, Li RH, Yuan WP, Xiang BD, Zheng MH, Yang T, Zhong JH, Li LQ. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget. 2017;8(31):51810–6.PubMedPubMedCentralCrossRef
64.
Chu YJ, Yang HI, Wu HC, Liu J, Wang LY, Lu SN, Lee MH, Jen CL, You SL, Santella RM, et al. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. Int J Cancer. 2017;141(4):711–20.PubMedPubMedCentralCrossRef
65.
Gao SS, Chen XY, Zhu RZ, Choi BM, Kim SJ, Kim BR. Dual effects of phloretin on aflatoxin B1 metabolism: activation and detoxification of aflatoxin B1. BioFactors. 2012;38(1):34–43.PubMedCrossRef
Metadata
Title
GSTM1 and GSTT1 null genotype increase the risk of hepatocellular carcinoma: evidence based on 46 studies
Authors
Shanli Li
Feng Xue
Yi Zheng
Pengtao Yang
Shuai Lin
Yujiao Deng
Peng Xu
Linghui Zhou
Qian Hao
Zhen Zhai
Ying Wu
Zhijun Dai
Shu Chen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0792-3

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients

Primary research

miR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma

Primary research

MMP3 activity rather than cortical stiffness determines NHE1-dependent invasiveness of melanoma cells

Review

CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target

Primary research

Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways

Hypothesis

The influence of PFK-II overexpression on neuroblastoma patients’ survival may be dependent on the particular isoenzyme expressed, PFKFB3 or PFKFB4
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits